Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings.
Rogliani PaolaBeatrice Ludovica RitondoMariachiara GabrieleMario CazzolaLuigino CalzettaPublished in: Expert review of clinical pharmacology (2020)
De-escalation to ICS is a procedure that allows optimizing the pharmacological therapy of stable COPD patients. While only a minority of severe COPD patients that are symptomatic and/or at high risk of exacerbation may really need of triple therapy, most patients should be de-escalated/switched from ICS-containing regimen toward dual bronchodilator therapy, or even to single bronchodilator regimen in patients affected by less severe form of COPD.
Keyphrases
- end stage renal disease
- chronic obstructive pulmonary disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- lung function
- cystic fibrosis
- mesenchymal stem cells
- intensive care unit
- minimally invasive
- bone marrow
- open label
- study protocol
- patient reported
- replacement therapy